In‐transit cutaneous squamous cell carcinoma
Authors: Luke S McLean and Danny Rischin
Published online: 2 May 2022
A 79-year-old man presented with painful lesions over his left arm on a background of non-Hodgkin lymphoma, which was well controlled on rituximab

A 79‐year‐old man presented with painful lesions over his left arm on a background of non‐Hodgkin lymphoma, which was well controlled on rituximab (Figure, A). Two years earlier, he had a poorly differentiated cutaneous squamous cell carcinoma of the left wrist excised (Figure, B, arrow). Fluorodeoxyglucose (FDG)‐positron emission tomography (PET) demonstrated extensive, avid cutaneous and subcutaneous lesions along the left upper limb and an axillary node. Biopsies confirmed poorly differentiated cutaneous squamous cell carcinoma. He commenced first line immunotherapy (cemiplimab 350 mg every 3 weeks) with concurrent radiotherapy, with a near complete resolution in his symptoms after seven cycles (Figure, B). FDG‐PET imaging at this time point confirmed a significant partial response in the left arm (Figure, C, blue arrow) but with progressive nodal disease in the left axilla extending to the supraclavicular region (Figure, C, red arrow). In‐transit disease represents an uncommon form of metastatic skin cancer related to lymphatic spread and is an important differential in immunocompromised patients, in whom it occurs more frequently.1
Competing interests
Danny Rischin receives institutional research funding from MSD, Bristol–Myers Squibb, GSK and Roche. He participates in trial steering committees and/or advisory boards (all uncompensated) for MSD, GSK, Regeneron and Sanofi.
References
- Levine DE, Karia PS, Schmults CD. Outcomes of patients with multiple cutaneous squamous cell carcinomas: a 10‐year single‐institution cohort study. JAMA Dermatol 2015; 151: 1220–1225.
Challenges and Opportunities for Strong and Dynamic Foundations in the Australian Cancer Plan
Ashley M. Hopkins, Andrew Rowland, Natansh D. Modi, Ceara Rickard, Mark Haseloff, Norma B. Bulamu, Imogen Ramsey, Niranjan Bidargaddi, Ganessan Kichenadasse, Michael J. Sorich, Kalinda E. Griffiths, Aideen McInerney-Leo, David M. Roder, Raymond J. Chan
Opportunities and Challenges to Achieving the Australian Cancer Plan Goal of World Class Health Systems for Optimal Cancer Care
Carolyn Ee, Ria Joseph, Elise Button, Stacey George, Makala Castelli, David Currow, Prue Cormie, Olivia Farrer, Michael Jefford, Nicolas H. Hart, Chad Y. Han, Deidre D. Morgan, Michael P. Osborn, Candice Oster, Joel Rhee, Anna Ugalde, Eric Yeung, Catherine Paterson
Maximising Cancer Prevention and Early Detection in the Australian Cancer Plan: Where Are We Now and What Should Come Next?
Erin L. Symonds, Billie Bonevski, Richard Edwards, Nathan J. Harrison, Sana Ishaque, Nicole M. Rankin, Sibel Saya, Renee J. Smith, Carolyn Ee
An Australian Narrative Review of Adoptive Cellular Therapies in Malignancy: Expanding Indications, Referral Pathways and Safety Beyond Specialist Centres
Sarah Childs, David Ma, Anthony Rodrigues, Jennifer Massey, Rasha Cosman, Venessa Chin, Laila Girgis, James Lynam, Peter Lau, Barbara Withers, Anthony M. Joshua, Ben Tran, Jayesh Desai, Simon J. Harrison, John Moore, Jia Liu
Peritoneal Tuberculosis and Chronic Myeloid Leukaemia: A Case of Hickam's Dictum
Zayn Al-Timimi, Gem Chew, Martin Browne, Christiaan Mostert
From Ambition to Action: Closing Policy, Equity and Implementation Gaps in the Australian Cancer Plan's ‘Enhanced Consumer Experience’
Carla Thamm, Elise Button, Oluwaseyifunmi A. Agbejule, Reegan Knowles, Karen van Gorp, Mark B. Pinkham, Meinir Krishnasamy, Alexandra L. McCarthy, Raymond J. Chan